調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Parkinson’s Diseases: World Drug Industry and Market 2016-2026

パーキンソン病治療薬の世界市場2016-2026

◆タイトル：Parkinson’s Diseases: World Drug Industry and Market 2016-2026
◆商品コード：VGAIN60623
◆調査・発行会社：visiongain
◆発行日：2016年5月
◆ページ数：172
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Sigle User（1名利用）GBP1,999 ⇒換算￥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算￥425,858見積依頼/購入/質問フォーム
Site License（全社内共有可）GBP4,999 ⇒換算￥709,858見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、パーキンソン病治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. パーキンソン病とその治療法の概要

3. パーキンソン病: 治療薬の世界市場 2016-2026

4. PD治療薬市場における主要企業 2016

5. 主要国市場 2016-2026

6. パーキンソン病治療に関する研究開発

7. PD治療薬市場の定性分析 2016

8. 調査インタビュー

9. 研究・分析の結論

Parkinson’s Diseases: World Drug Industry and Market 2016-2026 – our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:
• How is the Parkinson’s disease therapeutics market evolving?
• What is driving and restraining the Parkinson’s disease therapeutics market?
• How will political and regulatory factors influence the regional markets and submarkets?
• Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2016-2026 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
• What are the market shares of the Parkinson’s therapeutics disease market in 2015?
• How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
• What Parkinson’s disease drugs are in the development pipeline?
• How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
• How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales.

Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.

Parkinson’s Diseases: World Drug Industry and Market 2016-2026

Discover sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2026 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2026 for five therapeutic submarkets at world level:
• Dopaminergic Agents
• Dopamine Receptor Agonists
• MAO-inhibitors
• COMT-inhibitors
• Other Therapeutic Options

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Parkinson’s disease drugs
How will individual medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of three brands sold by four companies:
• Neupro (UCB)
• Azilect (Teva)
• Azilect (Lundbeck)
• Comtan/Stalevo (Novartis)

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015.

Our work also shows individual revenue forecasts to 2026 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations – Brazil, Russia, India and China

Leading companies and potential for market growth
In 2015 the overall world PD drug market generated $3217m. Visiongain predicts its revenues in 2020 to reach $3472m. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
• Novartis
• Teva
• UCB
• Roche
• Lundbeck

What affects producers of those medicines?
Our report discusses issues and events affecting that industry and market from 2015, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.
• Drugs and related technologies to transform the market
• Biomarkers
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

Our 172-page report provides 120 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Benefit your work now through our updated study, gaining original industry and market analysis:
• Revenues for Parkinson’s disease treatments to 2026 – assess that overall world drugs market’s potential and get forecasted revenues for the five leading sub-classes: dopaminergic agents, dopamine receptor agonists, COMT- and MAO-inhibitors and other therapeutic options.
• Products’ sales to 2026 – discover predicted revenues Neupro, Comtan/Stalevo, and Azilect and see how those medicines can compete and succeed
• National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth
• R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinions – examine participants, including Roche, Novartis, UCB and Lundbeck and get two exclusive interviews, helping your reputation for insight and staying ahead. Visiongain interviewed:
– Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
– Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York.
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.

【レポートの目次】

1. Report Overview
1.1 Overview of Findings: World Market Overview 2015 to 2026
1.2 Why You Should Read This Report
1.3 How This Report Delivers: Chapter Outlines
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About visiongain

2. Introduction to Parkinson’s Disease and its Treatments
2.1 What Causes Parkinson’s?
2.2 Motor Symptoms of Parkinson’s Disease
2.2.1 Tremor: The First Sign of PD
2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s
2.2.4 Postural Instability Manifests as PD Progresses
2.3 Neuropsychiatric Symptoms are Common in PD Patients
2.3.1 Behavioural Deficits are Often the Most Widespread
2.3.2 Cognitive Impairment can Impede Daily Tasks
2.3.3 Autonomic Dysfunction: Another Common Occurrence
2.4 Other Symptoms Associated with Parkinson’s
2.5 Parkinson’s Disease: Diagnosis and Treatment
2.5.1 Diagnosis is Difficult
2.5.2 Treatment Options – Therapeutic Classes

3. Parkinson’s Disease: World Drugs Market, 2016-2026
3.1 Sales of the Overall World PD Drugs Market, 2015-2026
3.2 Parkinson’s Disease: Market Segmentation, 2015
3.3 Overall PD Drug Market: Commercial Drivers and Restraints
3.4 Dopaminergic Agents: Foundation of PD Treatment
3.4.1 Levodopa Therapy
3.4.2 Patent Expiries Affect the Market
3.4.3 New Levodopa Therapies on the Horizon
3.4.4 Dopaminergic Agents: Market Projections to 2026
3.5 Dopamine Receptor Agonists: The Leading Class in 2016
3.5.1 Dopamine Agonists: A Front Line Drug
3.5.2 Advantages over L-Dopa Therapy
3.5.3 Leading Drugs in the Segment
3.5.4 A Healthy R&D Pipeline
3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026
3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
3.6.1 Entacapone: The Leading Drug in this Segment
3.6.2 Commercial Scope for COMT Inhibitors
3.6.3 COMT Inhibitors: Market Projections, 2016-2026
3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT?
3.7.1 MAO-B Inhibitor Therapeutics in the Market
3.7.2 New MAO-B Products in Development
3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026
3.7.4 Other Therapeutic Options: A Growing Opportunity
3.7.5 Generic Erosion in the PD Market
3.7.6 A Broad and Diverse Pharmaceutical Segment
3.7.7 Other Non-medication PD Therapies
3.7.8 The Pipeline Offers Disease Modifying Potential
3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026

4. Leading Companies in the PD Drug Market, 2016
4.1 PD: Novartis sales of Stalevo/Comtan
4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026
4.2 Teva’s Azilect: Past, Present and Future
4.2.1 Market Forecast for Azilect, 2015-2026
4.3 UCB’s Leading Neupro Patch Drug
4.3.1 Market Forecast for Neupro, 2016-2026
4.4 Other Market Players

5. The Leading National Markets, 2016-2026
5.1 Regional Breakdown of the World PD Drug Market, 2016
5.2 The World PD Drug Market: Regional Forecasts to 2026
5.3 The PD Drug Market in the US: The Largest Single National Market
5.3.1 Market Projections for the US, 2015-2026
5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026
5.4.1 Market Projections for the EU5, 2016-2026
5.4.2 EU5 Breakdown by Country, 2016
5.4.3 Market Projection for EU5 Countries, Regional Breakdown
5.4.4 Germany: The Largest EU5 Market
5.4.5 France: Strong Healthcare System – What’s Possible There?
5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market
5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales?
5.4.8 The PD Drug Market in Italy: Rising and Ageing Population
5.5 Japan has the Highest Proportion of Over-65s in the World
5.5.1 Predictions for Japanese PD Drug Market, 2016-2026
5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
5.6.1 Breakdown of BRIC Revenues by Country, 2016
5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2016-2026
5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future?
5.6.4 Russia’s Healthcare Market Gives Generic Sales Opportunities
5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines

6. Research and Development for Treating Parkinson’s Disease
6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
6.2 Growing Potential of Marketed Products: Phase IV Studies
6.3 Phase III Clinical Products Promising Potential in the PD market
6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa
6.3.2 Newron’s Safinamide Expected Launch in 2020
6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson’s Disease Psychosis
6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist
6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
6.3.8 Pitolisant: Addressing an Unmet Need
6.3.9 Northera: Oral Precursor of Norepinephrine
6.3.10 Targin by Mundipharm
6.3.11 Nurelinfor Levodopa-Induced Dyskinesia
6.3.12 SYN-115/120: Superior to Istradefylline?
6.4 Phase II PD Pipeline: Overview
6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
6.4.3 CVT-301: A Novel Intrapulmonary Approach
6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
6.4.6 Orient Addresses Sialorrhoea
6.4.7 NH004: Formulated with a Muco-Adhesive Property
6.4.8 VR040: A Reformulation of Apomorphine
6.4.9 AVP-923: A Novel Approach for LID-PD
6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
6.4.11 News for NeuroDerm’s Reformulations
6.5 Phase I and Pre-clinical PD Pipeline: Overview
6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa
6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
6.5.3 UCL Show Exenatide Potential in Parkinson’s
6.5.4 Titan Pharmaceuticals Develop a Novel Platform
6.6 Neuroprotective Drugs Offer Hope
6.6.1 Phytopharm and Cogane Development
6.6.2 The Potential of Dietary Supplements
6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s
6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s
6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
6.6.6 Antibody Targeting: The Coming of Age
6.7 Gene Therapy: Promising Research and Technology
6.7.1 ProSavin: Leading Gene Therapy Product
6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology

7. Qualitative Analysis of the PD Drug Market, 2016
7.1 SWOT Analysis of the PD Market
7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016
7.1.2 Opportunities and Threats There from 2016 Onwards
7.2 STEP Analysis of the PD Market
7.2.1 Social Implication of Living with PD
7.2.2 Technological Developments on the Horizon
7.2.3 Economic Pressures: Healthcare Budgeting
7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways

8. Research Interviews
8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
8.1.1 The Overall PD Market
8.1.2 Current Understanding of Stem Cell Therapy
8.1.3 ISCO’s Novel PD Programme
8.1.4 The Potential of Immune-Matching
8.1.5 The Controversy Surrounding Stem Cell Research
8.1.6 The Potential for Parthenogenesis in PD and Other Applications
8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York
8.2.1 A possible Cure
8.2.2 Future Potential: Research

9. Conclusions from the Research and Analysis
9.1 The World PD Market: Predictions to 2026
9.2 Which Therapeutic Class will Dominate the Market in 2026?
9.3 Disease Modification: The Ultimate Goal
9.4 The Future of the Industry and Market for Parkinson’s Medicines

Table 1.1 Parkinson’s disease Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
Table 1.2 Currency Exchange Rates, 2016
Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2015
Table 3.1 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.2 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%),
2021-2026
Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2016
Table 3.6 Formulations of Levodopa Therapy, 2016
Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2016
Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%),
CAGR (%), Market Share (%), 2021-2026
Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2015-2020
Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2021-2026
Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 4.1 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.2 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 4.3 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.3.1 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 4.4 Lundbeck’s Azliect Forecast: Revenues ($m), AGR (%), CAGR (%),
2015-2020
Table 4.4.1 Lundbeck’s Azliect Forecast: Revenues ($m), AGR (%), CAGR (%),
2021-2026
Table 4.5 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.5.1 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%),
Market Share (%), 2021-2026
Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2016
Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m),BRIC Market Shares (%), 2016
Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.1 Late-Stage PD Pipeline, 2016
Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013
Table 6.3 Phase II PD Pipeline, 2016
Table 6.4 Glutamatergic PD Pipeline, 2016
Table 6.5 Early-Stage Developments for PD, 2013
Table 6.6 Selected Gene Therapies in the PD Pipeline, 2015
Table 7.2 Parkinson’s Disease Drug Market: Opportunities and Threats, 2016-2026
Table 7.3 PD Drug Market: STEP Analysis, 2016

Figure 1.1 Global Parkinson’s disease Market Segmentation Overview, 2015
Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2016
Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2015-2026
Figure 3.4 PD Drug Market, Drivers and Restraints, 2015-2026
Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2015-2026
Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2016-2026
Figure 3.7 Dopaminergic Receptor Agonists Segment Forecast, Revenues ($m), 2015-2026
Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2015-2026
Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2015-2026
Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2015-2026
Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2015-2026
Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2016-2026
Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2015-2026
Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2015-2026
Figure 4.1 Revenues ($m) of Parkinson’s Drugs by Leading Company, 2013-2015
Figure 4.2 Orion’s Comtan/Stalevo Drug Revenues ($m) Forecast, 2014-2026
Figure 4.3 Teva’s Azilect Drug Revenues Forecast, 2014-2026
Figure 4.3.1 Lundbeck’s Azilect Drug Revenues Forecast, 2014-2026
Figure 5.1 PD Market Breakdown by Region, Market Shares (%), 2016
Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2026
Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2015-2026
Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2015-2026
Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2015-2026
Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share(%), 2016
Figure 5.7EU5 Regional Breakdown by Country, Revenues ($m), 2015-2026
Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2015-2026
Figure 5.9 German PD Drug Market, Revenues ($m), 2015-2026
Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2015-2026
Figure 5.11 French PD Drug Market, Revenues ($m), 2015-2026
Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2015-2026
Figure 5.13 UK PD Drug Market, Revenues ($m), 2015-2026
Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2015-2026
Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2015-2026
Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2015-2026
Figure 5.17 Italian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2015-2026
Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2015-2026
Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2015-2026
Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), BRIC Market Share (%), 2016
Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2015-2026
Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.24 Russian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.25 Indian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2015-2026
Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA genes, which Reduces Immune Rejection
Figure 9.1 PD Drug Market, Overall Revenues ($m), 2015, 2020 and 2026
Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2015, 2020 and 2026

★調査レポート[パーキンソン病治療薬の世界市場2016-2026] ( Parkinson’s Diseases: World Drug Industry and Market 2016-2026 / VGAIN60623) 販売に関する免責事項
[パーキンソン病治療薬の世界市場2016-2026] ( Parkinson’s Diseases: World Drug Industry and Market 2016-2026 / VGAIN60623) についてEメールでお問い合わせ
◆関連調査資料◆
  • パーキンソン病治療の世界市場2018-2028
    VGAIN803038 / visiongain / 2018年1月 / visiongain社が発行した当調査レポートでは、パーキンソン病治療の世界市場について調査・分析し、パーキンソン病治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・世界におけるパーキンソン病治療産業と市場のイントロダクション ・世界におけるパーキンソン病治療産業と市場予測～2028 ・世界におけるパーキンソン病治療市場治療薬：種類別市場予測～2028 ・世界におけるパーキンソン病治療産業と市場：販路別市場予測～2028 ・世界におけるパーキンソン病治療産業と市場：エンドユーザー別市場予測～2028 ・主要国におけるパーキンソン病治療市場2018-2028 ・北米におけるパーキンソン病治療産業と予測2018-2028 ・南米におけるパーキンソン病治療産業と予測2018-2028...Our new study reveals trends, R&D progress, and predicted revenues Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions: • How is the Parkinson’s disease therapeutics market evolving? • What is driving and restraining the Parkinson’s disease therapeutics market? • How will political and regulatory factors influence the regional markets and submarkets? • Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period? • What are the predictions for M&A activity, consolidation for existing players and the potential...
  • 糖尿病治療薬の世界市場2016-2026
    VGAIN60707 / visiongain / 2016年6月 / 当調査レポートでは、糖尿病治療薬の世界市場について調査・分析し、糖尿病治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 糖尿病治療薬の世界市場：概要 3. 糖尿病治療薬の世界市場 2016-2026 4. ヒトインスリンおよび類似体...Treating diabetes – benefit your influence by finding new R&D trends and sales prospects Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities. Visiongain’s updated report forecasts those revenues to 2026 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority. See what’s...
  • リウマチ性関節炎（RA）治療薬の世界市場2016-2026
    VGAIN81921 / visiongain / 2016年7月 / 当調査レポートでは、リウマチ性関節炎（RA）治療薬の世界市場について調査・分析し、リウマチ性関節炎（RA）治療薬の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. リウマチ性関節炎とは 3. リウマチ性関節炎治療薬の世界市場 4. リウマチ性関節炎市場における主要治療薬 5....Rheumatoid Arthritis – New Study Showing You Those Drugs’ Commercial Potentials Where is the arthritic treatments market heading? Visiongain’s updated report gives you forecasted revenues to 2026 for drugs treating rheumatoid arthritis (RA). There you find R&D trends, sales forecasting and commercial opportunities. Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field’s most promising and lucrative segments. Read on to scan features of that industry, find what drives it, and see what its future market could be worth. Forecasts and other...
  • 炎症性腸疾患（IBD）治療薬の世界市場2016-2026
    VGAIN6012611 / visiongain / 2016年1月 / 当調査レポートでは、炎症性腸疾患（IBD）治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・炎症性腸疾患（IBD）の概要 ・炎症性腸疾患（IBD）治療薬の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・炎症性腸疾患（IBD）治療薬の世界市場：医薬品別市場分析 ・炎症性腸疾患（IBD）治療薬の世界市場：研究開発パイプライン分析 ・市場環境分析 ・専門家の見解...Inflammatory Bowel Diseases – Your New Guide to Pharma R&D, Opportunities and Revenue Predictions What does the future hold for drugs treating inflammatory bowel diseases (IBD)? Those intestinal medicines retain high potential. Now you can explore sales forecasts and that industry’s research and development. Visiongain’s new report predicts those revenues to 2026 at overall world market, submarket, product and national level. There you assess commercial opportunities for therapies treating disorders including Crohn’s disease and ulcerative colitis. So please read on to examine those colonic treatments, seeing how high that industry’s sales can go. Discover what is possible for that large,...
  • 医薬品有力企業シリーズ： 眼薬メーカー上位25社分析2016-2026
    VGAIN60620 / visiongain / 2016年5月 / 当調査レポートでは、世界の眼薬メーカー上位25社について調査・分析し、以下の構成でお届けいたします。 1. レポート概要 2. 眼薬の概要 3. 眼薬: 世界市場 2016-2026 4....What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market. Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue...
  • 乾癬治療薬の世界市場予測2016-2026
    VGAIN60710 / visiongain / 2016年6月 / 当調査レポートでは、乾癬治療薬の世界市場について調査・分析し、乾癬治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 乾癬の概要 3. 乾癬治療薬の世界市場 2016-2026 4. 乾癬治療市場における主要治療薬...Psoriasis Drugs – Your Guide to R&D, Opportunities and Potential Revenues What does the future hold for treating psoriasis? Visiongain’s new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues. In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work’s purpose is to help you avoid falling behind in knowledge, missing business or losing influence. So read on now to explore that industry and discover...
  • アルツハイマー病治療・診断の世界市場予測2016-2026
    VGAIN60625 / visiongain / 2016年5月 / 当調査レポートでは、アルツハイマー病治療・診断の世界市場について調査・分析し、以下の構成でお届けいたします。 1. レポート概要 2. アルツハイマー病: 概要 3. アルツハイマー病治療・診断市場 2016-2026 4....Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies – our new study reveals trends, R&D progress, and predicted revenues Our new report discusses issues and events affecting the Alzheimer’s disease therapeutics and diagnostics market. Our new report provides qualitative analyses to answer these key questions: • How is the Alzheimer’s disease therapeutics and diagnostics market evolving? • What is driving and restraining the Alzheimer’s disease therapeutics and diagnostics market growth? • Which type of diagnostics will be the main drivers of the overall market from 2016 to 2026? • How will political and regulatory factors influence...
  • 遺伝子治療の世界市場：研究開発および売上予測2016-2026
    VGAIN6022516 / visiongain / 2016年1月 / 当調査レポートでは、遺伝子治療の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・遺伝子治療の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・遺伝子治療の世界市場：疾患別市場分析 ・遺伝子治療の研究開発パイプライン分析・予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...Gene Therapies – Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses What does the future hold for gene therapy? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities. Visiongain’s new 2016 report gives you revenue forecasts to 2026 for the world gene therapies market, submarkets and leading products. Avoid missing out. There investigate that applied molecular genetics, discovering its most promising uses. See what gains are possible. Please read on to explore that industry...
  • 男性/女性性機能障害治療薬の世界市場2016-2026
    VGAIN5122114 / visiongain / 2015年12月 / 当調査レポートでは、男性/女性性機能障害治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・男性/女性性機能障害治療薬の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・男性/女性性機能障害治療薬の世界市場：販売予測 ・男性/女性性機能障害治療薬の世界市場：新薬動向 ・男性/女性性機能障害治療薬の世界市場：研究開発パイプライン動向 ・男性/女性性機能障害治療薬の世界市場：地域別市場分析、市場規模予測 ・市場環境分析...Sexual Dysfunction Drugs – New Study Exploring Potentials of Established and Recently Approved Drugs, Industry Changes and Emerging Opportunities Are you interested in the future of treatments for sexual disorders? Our new analysis forecasts drug revenues for male and female treatments. There you explore sales results, R&D and opportunities, seeing changing trends and commercial prospects. Discover, from 2015, progress, opportunities and revenues. Drugs our study covers include treatments for erectile dysfunction (ED), Peyronie’s disease and female hypoactive sexual desire disorder (HSDD). See the effect of recent drug approvals. Please read on to explore that industry and see what future revenue...
  • 眼薬の世界市場予測2016-2026
    VGAIN81924 / visiongain / 2016年7月 / 当調査レポートでは、眼薬の世界市場について調査・分析し、眼薬の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 眼薬の概要 3. 眼薬の世界市場 4. 網膜障害治療薬市場：市場分析・予測 5....What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market. Our 334-page report provides 238 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆